
Tuesday, April 19, 2011 11:07:01 AM
Recent WINT News
- Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India • GlobeNewswire Inc. • 02/27/2025 01:00:00 PM
- Windtree Therapeutics, Inc. Announces Reverse Stock Split • GlobeNewswire Inc. • 02/18/2025 01:00:00 PM
- Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference • GlobeNewswire Inc. • 02/12/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2025 10:20:19 PM
- Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline • GlobeNewswire Inc. • 01/15/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2025 01:09:00 PM
- Windtree Announces the Addition of Leanne Kelly to Its Board of Directors • GlobeNewswire Inc. • 01/13/2025 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/08/2025 09:25:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2025 01:05:12 PM
- Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline • GlobeNewswire Inc. • 01/08/2025 01:00:00 PM
- Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference • GlobeNewswire Inc. • 12/16/2024 01:00:00 PM
- Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia • GlobeNewswire Inc. • 12/09/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2024 12:12:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2024 01:02:58 PM
- Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction • GlobeNewswire Inc. • 12/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2024 09:43:38 PM
- Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates • GlobeNewswire Inc. • 11/27/2024 09:05:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 01:53:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 01:01:49 PM
- Windtree Announces Leadership Transition Plan With Industry Veterans • GlobeNewswire Inc. • 11/14/2024 01:00:00 PM
- Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong • GlobeNewswire Inc. • 11/04/2024 01:00:00 PM
- Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3 • GlobeNewswire Inc. • 10/30/2024 12:00:00 PM
- Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World • GlobeNewswire Inc. • 10/23/2024 12:00:00 PM
- Windtree To Present at the ThinkEquity Conference on October 30th • GlobeNewswire Inc. • 10/21/2024 12:00:00 PM
- Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan • GlobeNewswire Inc. • 10/17/2024 12:15:00 PM
VAYK Proposes 100 million Buyback through Private Repurchases • VAYK • Feb 28, 2025 9:00 AM
ConnectM Eliminates an Additional $1.9 Million of Debt • CNTM • Feb 27, 2025 4:01 PM
Consumer Automotive Finance, Inc. Announces Nationwide Teleconference as It Transitions to Fifty 1 Labs, Inc. • CAFI • Feb 27, 2025 9:00 AM
VPR Brands Secures Settlement Agreement With POP Vapor, Reinforcing Commitment to Intellectual Property Protection • VPRB • Feb 27, 2025 8:49 AM
Wytec Begins Sales of Its Multi-Government AI Threat Detection Sensor Technology • WYTC • Feb 27, 2025 7:05 AM
VAYK Issues Clerical Correction to Feb 18 News Regarding Shareholder Premium • VAYK • Feb 26, 2025 10:32 AM